US Patent

US9422299 — Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists

Method of Use · Assigned to Euroscreen SA · Expires 2034-03-28 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects novel compounds of Formula I and their use in therapeutic treatments as selective NK-3 receptor antagonists.

USPTO Abstract

Novel compounds of Formula I and their use in therapeutic treatments.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3622 — Veozah

Patent Metadata

Patent number
US9422299
Jurisdiction
US
Classification
Method of Use
Expires
2034-03-28
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Euroscreen SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.